Sanofi

Sanofi-aventis

Martin Lorenz

Michael Wagner

Torsten Haack

Andreas Evers

Katrin Lorenz

Siegfried Stengelin

Bernd Henkel

Dieter Kadereit

Volkmar Wehner

Hans Matter

Francis Blanche

Ercole Rao

Beatrice Cameron

Christian Lange

Vincent Mikol

Martin Bossart

Jochen Kruip

Carsten Corvey

Tarik Dabdoubi

Nicolas Baurin

Christian Engel

Ingo Focken

Stefania Pfeiffer-Marek

Thomas Langer

Hauke Szillat

Katja Kroll

Peter Wonerow

Peter Florian

Markus Follmann

Reinhard Kirsch

Matthias Urmann

Anthony C Scotese

Kent W Neuenschwander

Marc Nazare

Henning Steinhagen

Béatrice Cameron

Armin Bauer

Thomas Leeuw

The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.

Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists

Compounds as peptidic GLP1/glucagon/GIP receptor agonists

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.

Functionalized Exendin-4 derivatives

Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists

Dual GLP-1/GIP receptor agonists

Non-acylated exendin-4 peptide analogues

Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists

Functionalized exendin-4 derivatives

The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab. The invention concerns a method for prevention of platelet activation when an anti-GP VI Fab is used.

Antagonist antibodies and their fab fragments against GPVI and uses thereof

The present disclosure relates to substituted isothiazolo[5,4-b]pyridine-2-carboxamides of the formula I, in which R1, R2, R3, R10, R11 and X are as defined in the claims. The compounds of the formula I are inhibitors of transglutaminases, in particular transglutaminase 2 (TGM2), and are suitable for the treatment of various diseases, for example degenerative joint diseases such as osteoarthritis. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals

The present invention relates to compounds of formula I, The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are inhibitors of the blood clotting enzymes, especially factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

Malonamide derivatives with antithrombotic activity

The present invention relates to compounds of the formula I, which exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses.

Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors

Growing community of inventors

Frankfurt am Main, Germany

Martin Lorenz